Sigyn Therapeutics, Inc.
SIGY· OTC
SIGYSigyn Therapeutics, Inc.
Filed Mar 31, 2023 · 10-K · 90 days after period end · 0001493152-23-009883
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | — | — | — | $5.34K |
| Net Income | -$858.94K | -$1.23M | -$840.18K | -$1.55K |
| EPS Diluted | — | — | — |
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
| $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end
